1,174 Followers on Owler

Agendia

Agendia researches and develops genomic-based molecular diagnostics for the prevention, treatment and monitoring of cancer. Read more

Mark R. Straley's photo - CEO of Agendia

CEO

Mark R. Straley

CEO Approval Rating

86/100

Founded:

2003

Status:

PrivateIndependent Company

AGENDIA TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Contextual Genomics is perceived as one of Agendia's biggest rivals. Contextual Genomics was founded in 2012, and is headquartered in Vancouver, British Columbia. Like Agendia, Contextual Genomics also competes in the Biotechnology space. Contextual Genomics generates $7.5M less revenue vs. Agendia.

NEO New Oncology is a top competitor of Agendia. NEO New Oncology is a Private company that was founded in 2012 in Cologne, North Rhine-Westphalia. Like Agendia, NEO New Oncology also works within the Biotechnology sector. Compared to Agendia, NEO New Oncology has 107 fewer employees.

Genomic Health is Agendia's #3 rival. Genomic Health is headquartered in Redwood City, California, and was founded in 2000. Genomic Health operates in the Biotechnology industry. Genomic Health generates 2,946% the revenue of Agendia.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $15M a good estimate for Agendia's revenue?

Agendia Acquisitions

No recent acquisitions found related to Agendia

Agendia Funding History

Since Agendia was founded in 2003, it has participated in 6 rounds of funding. In total Agendia has raised $157.0M. Agendia's last funding round was on Jul 2018 for a total of $35.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Jul 2018
$35M

Athyrium Capital Management LP

Equity
May 2012
$65M
Series E
Sep 2009
$23M
Series D
Aug 2007
$34M
Series B
Oct 2005
--

Since Agendia was founded in 2003, it has participated in 6 rounds of funding. In total Agendia has raised $157.0M. Agendia's last funding round was on Jul 2018 for a total of $35.0M

Agendia Investments

No recent investments found related to Agendia

Agendia News

March 12, 2021FinanzNachrichten

Landmark Long-Term Data from EORTC's MINDACT Study Published in The Lancet Oncology

Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that long-term... See more »
March 4, 2021FinanzNachrichten

Data Presented at the Miami Breast Cancer Conference Show MammaPrint and BluePrint Accurately Predict Pathologic Complete Response Rate Regardless of Age

Results support use of Agendia's genomic tests to better tailor pre-operative treatment and timing fo... See more »
February 25, 2021MarketScreener

Agendia to Participate in the Cowen 41st Annual Healthcare Conference

(marketscreener.com) Agendia, Inc., a world leader in precision oncology for breast cancer, today ann... See more »
January 11, 2021MarketScreener

Agendia to Participate in the 39th Annual J.P. Morgan Healthcare Conference

(marketscreener.com) Agendia, Inc., a world leader in precision oncology for breast cancer, today ann... See more »
December 11, 2020MarketScreener

Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint for Clinical Low Risk Breast Cancer Patients at SABCS 2020

(marketscreener.com) Agendia, Inc., a world leader in precision oncology for breast cancer, today ann... See more »
December 10, 2020FinanzNachrichten

Results from APHINITY Trial using BluePrint as a Biomarker Assay Presented at SABCS in Poster Spotlight Discussion

Agendia and Roche evaluate BluePrint's stratification of HER2+ early breast cancer patients treated w... See more »
December 10, 2020FinanzNachrichten

Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint

Clinical utility of molecular subtyping and risk of recurrence profiling highlighted in largest-ever ... See more »

Agendia Press Releases

August 25, 2020Cision Canada

MINDACT Study Shows MammaPrint Provides Widespread Health System Cost Savings

/CNW/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, announced the publica... See more »
May 29, 2020PR Newswire

Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment

IRVINE, Calif. and AMSTERDAM, May 29, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision... See more »
May 29, 2020PR Newswire

Long-Term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint

/PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announce... See more »
May 7, 2020StreetInsider

Agendia Co-Founder and Chief Scientific Officer Ren Bernards, PhD Elected to the National Academy of Sciences

IRVINE, Calif. and AMSTERDAM, May 7, 2020 /PRNewswire/...... See more »
April 16, 2020PR Newswire

Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients

IRVINE, Calif. and AMSTERDAM, April 16, 2020 /PRNewswire/ -- Agendia®, Inc., a world leader in precis... See more »
February 18, 2020PR Newswire

Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer

IRVINE, Calif. and AMSTERDAM, Feb. 18, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precisio... See more »
January 3, 2020StreetInsider

Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse

IRVINE, Calif. and AMSTERDAM, Jan. 3, 2020 /PRNewswire/ -- Agendia Inc., a world leader in precision ... See more »

Agendia Videos

Social Media

Agendia Headquarters

22 Morgan

Irvine, California92618

1-888-321-2732

Driving Directions »

Trending Companies

Agendia Summary

ABOUT

Overview

Agendia researches and develops genomic-based molecular diagnostics for the prevention, treatment and monitoring of cancer. Agendia was founded in 2003. Agendia's headquarters is located in Irvine, California, USA 92618. It has raised 157.0M in 6 roun...

CEO

Agendia's CEO, Mark R. Straley, currently has an approval rating of 86%. Agendia's primary competitors are Contextual Genomics, NEO New Oncology & Genomic Health.

Frequently Asked Questions about Agendia

  1. When was Agendia founded?

    Agendia was founded in 2003
  2. Who is Agendia's CEO?

    Agendia's CEO is Mark R. Straley
  3. How much revenue does Agendia generate?

    Agendia generates $15M in revenue
  4. How much funding does Agendia have?

    Agendia has historically raised $157M in funding
  1. Where is Agendia's headquarters?

    Agendia's headquarters is in Irvine California, USA
  2. How many employees does Agendia have?

    Agendia has 137 employees
  3. What sector does Agendia operate in?

    Agendia is in Pharmaceuticals, Biotechnology
  4. Who are Agendia's competitors?

    Agendia's top competitors are Contextual Genomics, NEO New Oncology, Genomic Health